EUVIMEDEUVIMED entdecken
EditorialKommentar

Expanding the role of bone-avid tracer cardiac single-photon emission computed tomography/ computed tomography: assessment of treatment response in transthyretin amyloid cardiomyopathy

Sharmila Dorbala iD

European Heart Journal - Cardiovascular Imaging · 2023

DOI: 10.1093/ehjci/jead108 ↗

Kurz gefasst

Editorial in der Zeitschrift European Heart Journal - Cardiovascular Imaging, 2023. Verfasst von Sharmila Dorbala. Beteiligte Einrichtung: Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Cardiac Amyloidosis Program, Cardiovascular Division, Department of Medi…. Hauptthemen laut MEDLINE: Amyloidosis, Cardiomyopathies. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 7 Literaturangaben. Gefördert von: NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This editorial refers to ‘Monitoring response to tafamidis with single-photon emission computed tomography/computed quantification in transthyretin amyloid cardiomyopathy’, by R. Rettl et al., https://doi.org/10.1093/ehjcho/jead030. Myocardial deposition of misfolded transthyretin (ATTR) protein as amyloid fibrils results in one of the most severe and progressive forms of restrictive heart failure—ATTR cardiomyopathy (ATTR-CM). Cardiac single-photon emission computed tomography (SPECT) with bone-avid tracers, technetium-99m-labeled pyrophosphate (PYP), 99mTc-3,3-diphosphono-1,2-pyrophosphate (DPD), or 99mTc-hydroxymethylene diphosphonate (HMDP), has revolutionized the evaluation and management of ATTR-CM.1 Novel therapies aimed to stabilize ATTR or silence TTR production are improving clinical outcomes in patients with ATTR-CM. Tafamidis, a TTR stabilizer therapy, compared to placebo, has been shown to improve survival and reduce heart failure hospitalizations and has become the standard of care for patients with ATTR-CM.2 Because of the increasing availability of targeted ATTR therapies, there is a growing need for assessment of treatment response in ATTR-CM. In this issue, R. Rettl et al. report their experience with serial myocardial 99mTc-DPD uptake quantified on SPECT/computed tomography (CT) before and after tafamidis therapy for ATTR-CM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmyloidosisCardiomyopathiesHumansPrealbuminSingle Photon Emission Computed Tomography Computed TomographyBenzoxazoles

Substanzen

PrealbumintafamidisBenzoxazoles

Autor:innen und Institutionen

  • Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Cardiac Amyloidosis Program, Cardiovascular Division, Department of Medicine, 75 Francis Street, Brigham and Women's Hospital, Boston, MA 0211…

ORCID-Profile: Sharmila Dorbala

Förderung

  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Dorbala, S. (2023). Expanding the role of bone-avid tracer cardiac single-photon emission computed tomography/ computed tomography: assessment of treatment response in transthyretin amyloid cardiomyopathy. European Heart Journal - Cardiovascular Imaging. https://doi.org/10.1093/ehjci/jead108

Vancouver

Dorbala S. Expanding the role of bone-avid tracer cardiac single-photon emission computed tomography/ computed tomography: assessment of treatment response in transthyretin amyloid cardiomyopathy. European Heart Journal - Cardiovascular Imaging. 2023. doi:10.1093/ehjci/jead108

BibTeX
@article{Dorbala2023,
  author = {Dorbala, Sharmila},
  title = {Expanding the role of bone-avid tracer cardiac single-photon emission computed tomography/ computed tomography: assessment of treatment response in transthyretin amyloid cardiomyopathy},
  journal = {European Heart Journal - Cardiovascular Imaging},
  year = {2023},
  doi = {10.1093/ehjci/jead108}
}
Kostenlos starten →